DunedinPACE: The Biological Speedometer

The Velocity of Decay

In the “Guesswork Era,” we used “Biological Age” clocks — like Horvath’s 2013 clock — which functioned like an odometer: they told you how many biological miles had already been accumulated relative to your chronological age. If your biological age was 45 but your chronological age was 40, the odometer showed 5 extra years of wear. Useful, but it couldn’t tell you whether you were currently accelerating or decelerating.

DunedinPACE operates as a speedometer. It doesn’t primarily measure how old you are; it measures how fast you are aging right now. A score of 1.0 means you are accumulating one year of biological aging for every chronological year. A score of 0.92 means you are aging at 92% of the average rate. A score of 1.12 means your biology is running 12% faster than average.

This rate-measurement property gives DunedinPACE a property no odometer-style clock can provide: sensitivity to intervention within months rather than years. The CALERIE trial confirmed this directly — 2 years of caloric restriction moved DunedinPACE scores while PhenoAge and GrimAge showed no significant change. The speedometer responds to the driver’s behaviour in real time. The odometer reflects decades of accumulated choices.

I. The Mechanism: Longitudinal Biology Distilled to DNA Methylation

DunedinPACE was developed in two stages, described in the foundational papers (Belsky et al., eLife, 2020 and 2022).

Stage 1 — The Pace of Aging Model: Researchers tracked 1,037 members of the Dunedin Study (1972–73 New Zealand birth cohort) across four measurement points at ages 26, 32, 38, and 45 — approximately 20 years of longitudinal organ-system data. At each visit, 19 biomarkers assessing cardiovascular, metabolic, renal, hepatic, immune, dental, and pulmonary system integrity were measured. Using linear mixed-effects modelling, each individual’s personal rate of decline across all 19 biomarkers was composited into a single Pace of Aging score. This is the biological ground truth the algorithm is trained to replicate.

Stage 2 — The Blood Test Distillation: Using machine learning (elastic-net regression) on Illumina EPIC array DNA methylation data from blood collected at age 45, the researchers identified 173 CpG sites whose methylation patterns collectively predict an individual’s 20-year Pace of Aging from a single blood draw. These 173 sites were selected specifically for test-retest reliability (ICC > 0.4), giving DunedinPACE a reliability coefficient of ICC = 0.96 in independent validation — meaning a result taken twice from the same blood sample will differ by less than 4% of variance. This is the technical foundation for using DunedinPACE as a serial intervention monitoring tool.

What the 173 CpG sites are reading: The methylation changes tracked by DunedinPACE are the downstream accumulation of biological stressors — chronic inflammation, oxidative stress, metabolic dysfunction, renal and hepatic strain, and immune system ageing. DunedinPACE is therefore not a measure of any single biological pathway; it is the integrated output of the entire organism’s organ-system integrity — which is why it cannot be moved by addressing any single pathway in isolation.

Forge Note — DunedinPACE vs. Older Clocks: The CALERIE trial provided the critical comparative test. PhenoAge and GrimAge (second-generation clocks) showed no significant change after 2 years of 25% caloric restriction in n=220 healthy non-obese adults. DunedinPACE showed a significant 2–3% slowing. This difference is not a flaw in the older clocks — they measure a different thing. It confirms that DunedinPACE’s rate-measurement architecture is specifically sensitive to the kind of short-to-medium-term physiological changes produced by lifestyle intervention.

II. Interpreting Your Score: Calibrated Population Context

A score of 1.0 represents the population average rate of aging — one biological year per chronological year. The distribution of DunedinPACE scores in the Dunedin cohort follows an approximately normal distribution centred on 1.0 with a standard deviation of approximately 0.13–0.15 units.

Forge Editorial Note — Score Table Recalibrated: The original article listed <0.80 as a realistically achievable “Forge Sovereign” tier. This requires correction. In the actual Dunedin Study population distribution, a DunedinPACE of 0.80 falls at approximately the 5th percentile or below — and the largest lifestyle intervention ever tested (25% caloric restriction for 2 years in the CALERIE RCT) produced a score reduction of approximately 0.02–0.03 units. A sustained DunedinPACE of 0.80 in a healthy mid-age adult would require an effect size far beyond what any current human trial has demonstrated. The table below is recalibrated to population-realistic ranges.

Score	Biological Velocity	Population Context	Forge Verdict
> 1.10	Significantly Accelerated	Top 25% fastest agers	Systemic Siege — Immediate Audit
1.00 – 1.10	Mildly Accelerated to Average	Average population	Active Friction
0.90 – 1.00	Moderately Decelerated	Top 25–40th percentile	Optimised Flux
< 0.90	Significantly Decelerated	Top 15th percentile	Forge Sovereign

On translating PACE scores to outcome estimates: The CALERIE data contextualises what a 2–3% DunedinPACE reduction means: an estimated 10–15% lower mortality risk in epidemiological translation — a magnitude comparable to a smoking cessation intervention. This is the evidence-grounded translation. Specific per-day longevity projections (e.g., “gaining X days per year”) are not established in the intervention literature and should not be presented as derived from this data.

Forge Verdict: A DunedinPACE below 0.95 in a healthy mid-age adult, confirmed across two sequential tests from the same lab platform, represents meaningful deceleration of biological aging relative to the population. The Forge protocol is working when DunedinPACE remains stable or declines over 12–18 month re-test intervals. The CALERIE data also confirms the corollary: aggressive lifestyle intervention produces real, measurable epigenetic effects at timescales of months to years — not decades.

III. The Forge Protocol: Throttling the Clock

Because DunedinPACE is the integrated output of 19-system organ integrity decline, it cannot be moved by optimising a single pathway. The most clinically validated lever in the human trial literature is caloric restriction — but the magnitude of effect from CR alone is modest (2–3%). The Forge approach is systemic reduction of biological friction across all five Pillars simultaneously, which is why DunedinPACE serves as the capstone metric that integrates progress across the entire Forge protocol.

The evidence hierarchy for DunedinPACE-shifting interventions:

Grade A (directly validated in human RCTs with DunedinPACE as a primary outcome):

• Caloric restriction / energy deficit: CALERIE RCT, n=220, 2–3% DunedinPACE reduction from 25% CR over 2 years (Waziry et al., Nature Aging, 2023). The mechanism operates through AMPK activation, reduced mTOR signalling, improved insulin sensitivity, lower visceral fat and its inflammatory output, and sirtuin pathway engagement.

Grade B (strong prospective associations; intervention evidence for upstream markers validated at sufficient scale):

• Chronic inflammation suppression (hs-CRP < 0.5 mg/L, IL-6 < 1.2 pg/mL): Multiple epigenetic clock studies (Belsky et al., eLife, 2020) confirm systemic inflammation as the strongest upstream predictor of DunedinPACE velocity. The interventions in the hs-CRP and IL-6 articles represent the highest-yield direct targets.
• Aerobic exercise: The same aerobic exercise protocol that reduces vascular stiffness (Bakali et al.) and maintains HRV also addresses the metabolic, inflammatory, and cardiovascular organ-system decline inputs tracked by DunedinPACE’s 19 biomarkers.
• Sleep architecture maintenance (Deep Sleep > 20% of total sleep): Slow-wave sleep is the primary window for growth hormone secretion, glymphatic clearance, and tissue repair — multiple DunedinPACE component biomarkers are directly impaired by sleep disruption.

Grade C (bio-plausible; early human trial evidence; DunedinPACE as primary outcome not yet established in powered RCTs):

• Methyl donors (TMG, methylfolate, B12): Provide the raw substrate for DNA methylation maintenance. Deficiency of methyl donors produces aberrant methylation drift — a direct contributor to epigenetic aging. The evidence for supplementation in non-deficient individuals is insufficient to generate a specific DunedinPACE effect size. Test-and-correct for B12 and folate deficiency before supplementing.
• Alpha-Ketoglutarate (AKG): A TCA cycle metabolite and co-factor for ten-eleven translocation (TET) enzymes, which mediate active DNA demethylation. Demidenko et al. (Rejuvenation Research, 2021, n=42) showed calcium AKG reduced GrimAge by approximately 8 years in a small uncontrolled trial. A subsequent analysis of multi-intervention protocols showed epigenetic clock improvements. Importantly, GrimAge improvements do not directly translate to DunedinPACE improvements — they are measuring different constructs. AKG is a promising Grade C candidate; powered DunedinPACE-specific RCT evidence is pending.
• Vitamin D3 (correcting deficiency): D3 modulates over 2,000 gene expression sites via the VDR, including many involved in immune regulation and DNA repair. Deficiency is associated with accelerated epigenetic aging in several cohort studies. Effect of supplementation on DunedinPACE specifically has not been tested in a powered RCT; the mechanism supports it as a contributor to the systemic friction reduction that drives DunedinPACE.

IV. Actionable Resilience: The Audit

1. Annual Testing — Same Lab, Same Platform. DunedinPACE’s test-retest ICC is 0.96, making it one of the most technically reliable epigenetic measures available. However, cross-platform comparisons are unreliable — different normalisation pipelines (TruDiagnostic, myDNAge, Elysium Index) produce different absolute score distributions. To generate meaningful serial data, every test must be from the same provider using the same processing pipeline. A score of 0.94 from TruDiagnostic cannot be meaningfully compared against 0.94 from a different platform.

2. Wait 6–12 Months After a Major Protocol Change. DunedinPACE reflects the accumulated pace of recent biological aging — not the instantaneous state of a single day. Because the 173 CpG sites integrate the signal of weeks-to-months of biological change, a protocol shift made 4 weeks before testing will not be reflected. A 6-month minimum post-change interval before re-testing is the appropriate window for detecting intervention effects on DunedinPACE. For major multi-system protocol changes, 12 months provides a cleaner signal.

3. Never Interpret DunedinPACE in Isolation. DunedinPACE tells you how fast you are aging overall. It does not tell you why. If your score is elevated or rising, the cross-system audit is the next step: check hs-CRP and IL-6 (Pillar 04), HbA1c and fasting insulin (Pillar 01), Cystatin C (Pillar 04), HRV trend (Pillar 03), and cfPWV/Vascular Age (Pillar 02). Each of these markers contributes to the 19-biomarker composite. A rising DunedinPACE score despite no lifestyle changes suggests an emerging pathological process in one or more of these domains.

4. Treat the First Result as a Baseline, Not a Verdict. Because DunedinPACE scores are normally distributed around 1.0 with SD ~0.13, a first-time result of 1.05 places you approximately 0.4 standard deviations above the mean — mildly elevated, worth acting on, but not a crisis signal. The trajectory across three annual tests (year 1, year 2, year 3) is the clinically actionable information. A score of 1.05 holding stable over three years while on an active protocol is a neutral-to-positive finding. A score declining from 1.08 to 1.02 to 0.97 over three years is the outcome you are targeting.

5. The CALERIE Calibration Benchmark. The most aggressive lifestyle-only intervention ever tested in a powered human RCT (25% sustained caloric restriction for 2 years) produced a 2–3% DunedinPACE reduction. Use this as the upper bound for what single-intervention lifestyle changes can achieve in 2 years. Compound protocol optimisation across all five Forge Pillars simultaneously should, in principle, stack effects across the 19-system composite — but no trial has tested the full multi-system longevity protocol design against DunedinPACE as a primary endpoint. The CALERIE benchmark is the best available calibration point.

References

• Belsky D.W. et al., eLife (2020): “Quantification of the pace of biological aging in humans through a blood test, the DunedinPoAm DNA methylation algorithm.” Dunedin Study n=954; foundational speedometer architecture; validation in 3 external cohorts; association with physical function, cognitive performance, facial aging, and mortality. DOI: 10.7554/eLife.54870
• Belsky D.W. et al., eLife (2022): “DunedinPACE, a DNA methylation biomarker of the pace of aging.” Dunedin Study n=1,037, ages 26–45, 4 measurement points; 19 organ-system biomarkers; 173-CpG elastic-net algorithm; ICC=0.96 test-retest reliability; validated in 5 external datasets; DunedinPACE adds incremental prediction beyond GrimAge for morbidity, disability, and mortality. DOI: 10.7554/eLife.73420
• Waziry R. et al., Nature Aging (2023): “Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial.” RCT, n=220, 2-year 25% CR. DunedinPACE slowed 2–3% (P < 0.05); PhenoAge and GrimAge showed no significant change. 2–3% DunedinPACE slowing translates to 10–15% mortality risk reduction in epidemiological studies. First human RCT evidence that DunedinPACE is directly modifiable by intervention. DOI: 10.1038/s43587-022-00357-y
• Higgins-Chen A.T. et al., Nature Aging (2022): “A computational solution for bolstering reliability of epigenetic clocks: implications for clinical trials and longitudinal tracking.” Principal components analysis improves clock reliability; contextualises DunedinPACE’s superior test-retest reliability vs. GrimAge and PhenoAge for serial monitoring. DOI: 10.1038/s43587-022-00248-2
• Demidenko O. et al., Rejuvenation Research (2021): “Rejuvenation of Three Epigenetic Clocks upon a 9-Month Vitality Renewal Program by Young Blood Plasma Injection, Leronlimab, and Epitalon.” Preliminary AKG + multi-intervention trial; GrimAge reductions; Grade C for DunedinPACE-specific AKG efficacy pending powered RCT. DOI: 10.1089/rej.2021.0073
• Consensus 14 Metadata: “DunedinPACE as the Biological Roadmap capstone — integration of all Pillar-level biomarker trajectories (hs-CRP, IL-6, HbA1c, Fasting Insulin, ApoB, Cystatin C, Vascular Age, HRV, Deep Sleep %, Grip Strength, SMMI, Cognitive Processing Speed) into a single biological velocity readout.”